The long term goal of our program is to develop novel broad spectrum chemotherapeutics that can be used for Phase 1 clinical trials for treating the diseases caused by priority pathogens such as Francisella tularensis, Burkholderia pseudomallei and Yersinia pestis. We have developed a series of high affinity inhibitors of the fatty acid biosynthesis enoyl reductase (Fabl) enzyme that demonstrate in vitro potency against F. tularensis, M. tuberculosis and B. pseudomallei, and are active in an animal model of tularemia, confirming the validity of the target and of our approach. The goal of the present project is to dramatically improve the therapeutic dose by determining how factors such as formulation and modes of delivery, and structural modifications impact the in vivo antibacterial activity of the compounds. Studies will initially focus on the category A pathogen F. tularensis and the tularemia model of infection as this is the system in which we have had the most success. As the project evolves the information gained will be used to drive additional studies on B. pseudomallei and the melioidosis animal model of infection and Y. pestis. We will perform lead optimization studies on the Fabl inhibitors to: (i) improve pharmacology and reduce metabolic liability, (ii) facilitate deliverability/bioavailability, (iii) improve release kinetics, and (iv) assess alternative routes of delivery to optimize candidates for preclinical studies and performing required benchmarks for submission of an IND application. Our goal of developing inhibitors with enhanced in vivo efficacy will be achieved with the following Specific Aims:
Aim 1 : Effect of formulation and method of delivery on PK and in vivo antibacterial activity.
Aim 2 : Introduction of structural modifications to improve PK/PD.
Aim 3 : Extension to Other Priority Pathogens.

Public Health Relevance

This proposal is to enhance the therapeutic effect of broad spectrum chemotherapeutics with efficacy against F. tularensis and B. pseudomallei and Y. pestis infections. In addition, such chemotherapeutics can be used to treat bacterial agents with significant health relevance, particularly Gram-positive pathogens, including MRSA and Gram-negative pathogens including B. cenocepacia, A. baumannii, and P. aeruginosa

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI082164-02
Application #
7932903
Study Section
Special Emphasis Panel (ZAI1-MMT-M (J2))
Program Officer
Xu, Zuoyu
Project Start
2009-09-17
Project End
2013-02-28
Budget Start
2010-09-01
Budget End
2013-02-28
Support Year
2
Fiscal Year
2010
Total Cost
$978,895
Indirect Cost
Name
Colorado State University-Fort Collins
Department
Microbiology/Immun/Virology
Type
Schools of Veterinary Medicine
DUNS #
785979618
City
Fort Collins
State
CO
Country
United States
Zip Code
80523
Ojima, Iwao; Awasthi, Divya; Wei, Longfei et al. (2017) Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ. J Fluor Chem 196:44-56
Knudson, Susan E; Cummings, Jason E; Bommineni, Gopal R et al. (2016) Formulation studies of InhA inhibitors and combination therapy to improve efficacy against Mycobacterium tuberculosis. Tuberculosis (Edinb) 101:8-14
Knudson, Susan E; Awasthi, Divya; Kumar, Kunal et al. (2015) Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. J Antimicrob Chemother 70:3070-3
Knudson, Susan E; Awasthi, Divya; Kumar, Kunal et al. (2014) A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis. PLoS One 9:e93953
Knudson, Susan E; Kumar, Kunal; Awasthi, Divya et al. (2014) In vitro-in vivo activity relationship of substituted benzimidazole cell division inhibitors with activity against Mycobacterium tuberculosis. Tuberculosis (Edinb) 94:271-6
Awasthi, Divya; Kumar, Kunal; Knudson, Susan E et al. (2013) SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents. J Med Chem 56:9756-70
Slayden, Richard A; Jackson, Mary; Zucker, Jeremy et al. (2013) Updating and curating metabolic pathways of TB. Tuberculosis (Edinb) 93:47-59
Kumar, Kunal; Awasthi, Divya; Lee, Seung-Yub et al. (2013) Benzimidazole-based antibacterial agents against Francisella tularensis. Bioorg Med Chem 21:3318-26
Liu, Nina; Cummings, Jason E; England, Kathleen et al. (2011) Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei. J Antimicrob Chemother 66:564-73
Kingry, Luke C; Troyer, Ryan M; Marlenee, Nicole L et al. (2011) Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect 13:261-75